Amgen Financials

AMGN Stock  USD 294.00  0.53  0.18%   
Based on the analysis of Amgen's profitability, liquidity, and operating efficiency, Amgen Inc may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Amgen's Cash is very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 70.2 B, while Property Plant And Equipment Net is likely to drop about 3.6 B. Key indicators impacting Amgen's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Net Profit Margin0.180.2383
Way Down
Pretty Stable
Return On Assets0.120.0691
Way Up
Slightly volatile
Return On Equity1.131.0778
Sufficiently Up
Slightly volatile
Debt Equity Ratio10.8910.3679
Sufficiently Up
Slightly volatile
Current Ratio1.571.6492
Notably Down
Slightly volatile
Investors should never underestimate Amgen's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Amgen's cash flow, debt, and profitability to make informed and accurate decisions about investing in Amgen Inc.

Net Income

7.05 Billion

  
Understanding current and past Amgen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Amgen's financial statements are interrelated, with each one affecting the others. For example, an increase in Amgen's assets may result in an increase in income on the income statement.

Amgen Earnings Geography

Amgen Stock Summary

Amgen competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 24200 people.
Foreign Associate
  Mexico
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS0311621009
CUSIP031162100
LocationCalifornia; U.S.A
Business AddressOne Amgen Center
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.amgen.com
Phone805 447 1000
CurrencyUSD - US Dollar

Amgen Key Financial Ratios

Amgen Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets59.7B62.9B61.2B65.1B97.2B102.0B
Other Current Liab8.5B9.2B9.9B11.2B13.6B14.3B
Net Debt23.9B26.7B25.3B31.3B53.7B56.4B
Retained Earnings(21.3B)(21.4B)(24.6B)(28.6B)(26.5B)(25.2B)
Cash6.0B6.3B8.0B7.6B10.9B11.5B
Net Receivables4.1B4.5B4.9B5.6B7.9B8.3B
Other Current Assets1.9B2.1B2.4B2.4B1.9B2.7B
Total Liab50.0B53.5B54.5B61.5B90.9B95.5B
Total Current Assets18.4B21.1B19.4B22.2B30.3B15.2B
Short Term Debt3.0B244M232M1.7B1.6B1.0B
Inventory3.6B3.9B4.1B4.9B9.5B10.0B
Accounts Payable1.4B1.4B1.4B1.6B1.6B1.7B
Capital Stock31.5B31.8B32.1B32.5B33.1B27.5B
Common Stock31.5B31.8B32.1B32.5B33.1B27.5B
Other Assets955M1.3B6.5B2.2B2.5B1.4B
Long Term Debt27.0B32.9B33.2B37.4B63.2B66.3B
Good Will14.7B14.7B14.9B15.5B18.6B14.4B
Intangible Assets19.4B16.6B15.2B16.1B32.6B34.3B
Other Liab9.9B9.0B9.1B7.9B9.1B5.1B
Net Tangible Assets(24.4B)(21.9B)(23.4B)(27.9B)(25.2B)(23.9B)
Long Term Debt Total27.0B32.9B33.2B37.4B43.0B29.9B

Amgen Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense1.3B1.3B1.2B1.4B2.9B3.0B
Total Revenue23.4B25.4B26.0B26.3B28.2B29.6B
Gross Profit19.0B19.3B19.5B19.9B19.7B20.7B
Operating Income9.7B5.8B6.0B5.3B7.9B4.1B
Ebit9.7B9.3B9.1B8.8B7.9B4.6B
Ebitda10.4B12.9B12.5B12.1B7.9B5.4B
Cost Of Revenue4.4B6.2B6.5B6.4B8.5B8.9B
Income Before Tax9.1B8.1B6.7B7.3B7.9B4.0B
Net Income7.8B7.3B5.9B6.6B6.7B7.1B
Income Tax Expense1.3B869M808M794M1.1B830.4M
Research Development4.1B4.2B4.8B4.4B4.8B2.9B
Tax Provision1.3B869M808M794M1.2B1.4B
Interest Income928M674M753M256M230.4M218.9M
Net Interest Income(536M)(1.0B)(1.2B)(1.4B)(2.5B)(2.3B)

Amgen Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory(66M)(215M)(165M)(742M)491M515.6M
Change In Cash(908M)229M1.7B(360M)3.3B3.5B
Free Cash Flow8.5B9.9B8.4B8.8B7.4B4.5B
Depreciation2.2B3.6B3.4B3.4B4.1B4.3B
Other Non Cash Items(186M)(195M)1.3B1.3B(991M)(941.5M)
Capital Expenditures618M608M880M936M1.1B663.6M
Net Income7.8B7.3B5.9B6.6B6.7B3.4B
End Period Cash Flow6.0B6.3B8.0B7.6B10.9B11.5B
Change To Netincome205M(152M)3.4B485M557.8M379.4M
Investments20.0B(4.7B)733M(6.0B)(2.6B)(2.5B)
Change Receivables(504M)(427M)(429M)(746M)(671.4M)(637.8M)
Net Borrowings(4.5B)2.5B795M6.6B6.0B6.3B
Dividends Paid3.5B3.8B4.0B4.2B4.6B2.9B

Amgen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Amgen's current stock value. Our valuation model uses many indicators to compare Amgen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amgen competition to find correlations between indicators driving Amgen's intrinsic value. More Info.
Amgen Inc is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about  0.08  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Amgen Inc is roughly  12.11 . At this time, Amgen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amgen's earnings, one of the primary drivers of an investment's value.

Amgen's Earnings Breakdown by Geography

Amgen Inc Systematic Risk

Amgen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Amgen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Amgen Inc correlated with the market. If Beta is less than 0 Amgen generally moves in the opposite direction as compared to the market. If Amgen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Amgen Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Amgen is generally in the same direction as the market. If Beta > 1 Amgen moves generally in the same direction as, but more than the movement of the benchmark.

Amgen Thematic Clasifications

Amgen Inc is part of several thematic ideas from Health Management to Drugs. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Amgen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amgen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Amgen growth as a starting point in their analysis.

Price Earnings To Growth Ratio

7.72

At this time, Amgen's Price Earnings To Growth Ratio is very stable compared to the past year.

Amgen November 26, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Amgen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Amgen Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Amgen Inc based on widely used predictive technical indicators. In general, we focus on analyzing Amgen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Amgen's daily price indicators and compare them against related drivers.
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.621
Dividend Share
8.88
Earnings Share
7.83
Revenue Per Share
60.641
Quarterly Revenue Growth
0.232
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.